Pfizer Total Non-Operating Income/Expense 2010-2024 | PFE
Pfizer annual/quarterly total non-operating income/expense history and growth rate from 2010 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
- Pfizer total non-operating income/expense for the quarter ending September 30, 2024 was $-0.243B, a 34.25% increase year-over-year.
- Pfizer total non-operating income/expense for the twelve months ending September 30, 2024 was $-0.814B, a 275.05% decline year-over-year.
- Pfizer annual total non-operating income/expense for 2023 was $0.835B, a 484.79% decline from 2022.
- Pfizer annual total non-operating income/expense for 2022 was $-0.217B, a 104.45% decline from 2021.
- Pfizer annual total non-operating income/expense for 2021 was $4.878B, a 502.14% decline from 2020.
Pfizer Annual Total Non-Operating Income/Expense
(Millions of US $) |
| 2023 |
$835 |
| 2022 |
$-217 |
| 2021 |
$4,878 |
| 2020 |
$-1,213 |
| 2019 |
$4,610 |
| 2018 |
$-2,077 |
| 2017 |
$-1,416 |
| 2016 |
$-3,794 |
| 2015 |
$-2,860 |
| 2014 |
$-1,009 |
| 2013 |
$532 |
| 2012 |
$-4,022 |
| 2011 |
$-2,486 |
| 2010 |
$-3,941 |
| 2009 |
$-285 |
Pfizer Quarterly Total Non-Operating Income/Expense
(Millions of US $) |
| 2024-09-30 |
$-243 |
| 2024-06-30 |
$-1,107 |
| 2024-03-31 |
$-680 |
| 2023-12-31 |
$1,216 |
| 2023-09-30 |
$-181 |
| 2023-06-30 |
$75 |
| 2023-03-31 |
$-275 |
| 2022-12-31 |
$846 |
| 2022-09-30 |
$59 |
| 2022-06-30 |
$-772 |
| 2022-03-31 |
$-350 |
| 2021-12-31 |
$835 |
| 2021-09-30 |
$1,696 |
| 2021-06-30 |
$1,343 |
| 2021-03-31 |
$1,004 |
| 2020-12-31 |
$-106 |
| 2020-09-30 |
$-1,878 |
| 2020-06-30 |
$955 |
| 2020-03-31 |
$-184 |
| 2019-12-31 |
$-2,940 |
| 2019-09-30 |
$7,768 |
| 2019-06-30 |
$-126 |
| 2019-03-31 |
$-92 |
| 2018-12-31 |
$-3,220 |
| 2018-09-30 |
$414 |
| 2018-06-30 |
$551 |
| 2018-03-31 |
$178 |
| 2017-12-31 |
$-1,352 |
| 2017-09-30 |
$-79 |
| 2017-06-30 |
$75 |
| 2017-03-31 |
$-60 |
| 2016-12-31 |
$-979 |
| 2016-09-30 |
$-1,417 |
| 2016-06-30 |
$-1,068 |
| 2016-03-31 |
$-330 |
| 2015-12-31 |
$-2,190 |
| 2015-09-30 |
$-661 |
| 2015-06-30 |
$-55 |
| 2015-03-31 |
$46 |
| 2014-12-31 |
$-345 |
| 2014-09-30 |
$-94 |
| 2014-06-30 |
$53 |
| 2014-03-31 |
$-623 |
| 2013-12-31 |
$18 |
| 2013-09-30 |
$-411 |
| 2013-06-30 |
$1,070 |
| 2013-03-31 |
$-145 |
| 2012-12-31 |
$-739 |
| 2012-09-30 |
$-937 |
| 2012-06-30 |
$-688 |
| 2012-03-31 |
$-1,658 |
| 2011-12-31 |
$-689 |
| 2011-09-30 |
$-547 |
| 2011-06-30 |
$-423 |
| 2011-03-31 |
$-827 |
| 2010-12-31 |
$-905 |
| 2010-09-30 |
$-2,349 |
| 2010-06-30 |
$-275 |
| 2010-03-31 |
$-412 |
| 2009-12-31 |
$-110 |
| 2009-09-30 |
$-160 |
| 2009-06-30 |
$-72 |
| 2009-03-31 |
$57 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
